

Dr Farah Al-Beidh
Clinical Trial Manager
Imperial College London / ICNARC
Tel: 020 7831 6878
Mobile: 07714051401
Fax: 020 7831 6879
Email: ukremap-cap@icnarc.org

Barbara Cuddon
REC Manager
Health Research Authority
Skipton House, 80 London Road, London SE1 6LH

Dear Barbara,
Re: Study Title: Randomized, Embedded, Multi-factorial, Adaptive Platform Trial for community -Acquired Pneumonia
REC reference: 18/lo/0660
EudraCT number: 2015-002340-14
IRAS project ID: 237150
Substantial amendment 22 (AM022) Expedited Approval

I am submitting substantial amendment AM022 for the REMAP-CAP study.

This involves the addition of an Antiplatelet Domain specific Appendix:

REMAP-CAP – Antiplatelet Domain v1.0 24/08/2020 CLEAN

Changes to IS_CF for COVID-19 suspected /confirmed patients now includes a section for randomising to the antiplatelet domain for pre-ICU and ICU patients. We have also added space for witness consent in the event that the patient or the Personal Legal representative is not able to physically sign the consent form.

We have also listed the new IMPs for the Antiplatelet Domain.

Many Thanks

Farah

Farah Al-Beidh PhD
UK REMAP-CAP Trial Manager
Imperial College London / ICNARC
Tel: 020 7831 6878
Mobile: 07714051401
Fax: 020 7831 6879
Email: ukremap-cap@icnarc.org

Coordinating Centers

EUROPE
University Medical Center Utrecht
Heidelberglaan 100
3584 CX
THE NETHERLANDS
Phone +31 (0) 6 277 444 77
Email prepare_icu@umcmrecht.nl

NEW ZEALAND
The Medical Research Institute of
New Zealand
Private Bag 7902, Newtown,
Wellington 6242,
NEW ZEALAND
Phone +64 4 805 0147
Email anne.turner@mrnz.ac.nz

AUSTRALIA
The Australian and New Zealand
Intensive Care Research Centre,
Monash University
Level 3, 533 St Kilda Road
Melbourne, Victoria, 3004
AUSTRALIA
Phone +61 3 9903 0247
Email anzicrc@med.monash.edu